Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression

Angiogenesis

Volumn 13, Issue 4, 2010, Pages 327-335

  Greenberger, Shoshana ^a   Adini, Irit ^a   Boscolo, Elisa ^a   Mulliken, John B ^a   Bischoff, Joyce ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Hemangioma derived stem cells; Infantile hemangioma; Nuclear factor kappa light chain enhancer of activated B cells (NF B); Urokinase plasminogen activator receptor (uPAR); VEGF

Indexed keywords

6 AMINO 4 (4 PHENOXYPHENYLETHYLAMINO)QUINAZOLINE; BORTEZOMIB; CD31 ANTIGEN; CORTICOSTEROID; DEXAMETHASONE; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MONOCYTE CHEMOTACTIC PROTEIN 1; QUINAZOLINE DERIVATIVE; STEROID; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; VASCULOTROPIN A; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; BINDING AFFINITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENE TARGETING; HEMANGIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STEM CELL; CANCER STEM CELL; CAPILLARY HEMANGIOMA; CHILD; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEWBORN; PATHOLOGY; PRESCHOOL CHILD; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOMA, CAPILLARY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; NF-KAPPA B; PYRAZINES; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952356422     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-010-9189-6     Document Type: Article

References (58)

1. Mulliken J (1988) Diagnosis and natural history of hemangiomas. In: Young AE, Mulliken JB (eds) Vascular birthmarks: hemangiomas and malformations. WB Saunders, Philadelphia
2. Drolet BA, Esterly NB, Frieden IJ (1999) Hemangiomas in children. N Engl J Med 341:173-181 (Pubitemid 29325746)
3. Frieden IJ, Eichenfield LF, Esterly NB, Geronemus R, Mallory SB (1997) Guidelines of care for hemangiomas of infancy. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol 37:631-637 (Pubitemid 27446736)
4. Khan ZA, Boscolo E, Picard A, Psutka S, Melero-Martin JM, Bartch TC, Mulliken JB, Bischoff J (2008) Multipotential stem cells recapitulate human infantile hemangioma in immunodeficient mice. J Clin Invest 118:2592-2599 (Pubitemid 351949786)
5. Greenberger S, Boscolo E, Adini I, Mulliken JB, Bischoff J (2010) Corticosteroid suppression of VEGF-A in infantile hemangioma- derived stem cells. N Engl J Med 362:1005-1013
6. Wang Y, Dang J, Wang H, Allgayer H, Murrell GA, Boyd D (2000) Identification of a novel nuclear factor-kappaB sequence involved in expression of urokinase-type plasminogen activator receptor. Eur J Biochem 267:3248-3254 (Pubitemid 30341152)
7. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 272:31092-31099 (Pubitemid 27527558)
8. Karst AM, Gao K, Nelson CC, Li G (2009) Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer 124:494-501
9. Vincenti MP, Coon CI, Brinckerhoff CE (1998) Nuclear factor kappaB/p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1beta-stimulated synovial fibroblasts. Arthritis Rheum 41:1987-1994 (Pubitemid 28506689)
10. Hozawa S, Nakamura T, Nakano M, Adachi M, Tanaka H, Takahashi Y, Tetsuya M, Miyata N, Soma H, Hibi T (2008) Induction of matrix metalloproteinase-1 gene transcription by tumour necrosis factor alpha via the p50/p50 homodimer of nuclear factor-kappa B in activated human hepatic stellate cells. Liver Int 28:1418-1425
11. Kumar A, Takada Y, Boriek AM, Aggarwal BB (2004) Nuclear factor-kappaB: its role in health and disease. J Mol Med 82:434-448 (Pubitemid 39044283)
12. Yamamoto Y, Gaynor RB (2001) Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr Mol Med 1:287-296 (Pubitemid 33773312)
13. Stehlik C, de Martin R, Kumabashiri I, Schmid JA, Binder BR, Lipp J (1998) Nuclear factor (NF)-kappaB-regulated X-chromosome- linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis. J Exp Med 188:211-216 (Pubitemid 28328620)
14. Brouard S, Berberat PO, Tobiasch E, Seldon MP, Bach FH, Soares MP (2002) Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alphamediated apoptosis. J Biol Chem 277:17950-17961 (Pubitemid 34967606)
15. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C (1996) A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem 271:18068-18073 (Pubitemid 26250793)
16. Tabruyn SP, Griffioen AW (2007) A new role for NF-kappaB in angiogenesis inhibition. Cell Death Differ 14:1393-1397 (Pubitemid 47086727)
17. Aurora AB, Biyashev D, Mirochnik Y, Zaichuk TA, Sanchez- Martinez C, Renault MA, Losordo D, Volpert OV NF-{kappa}B balances vascular regression and angiogenesis via chromatin remodeling and NFAT displacement. Blood
18. Kisseleva T, Song L, Vorontchikhina M, Feirt N, Kitajewski J, Schindler C (2006) NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 116:2955-2963 (Pubitemid 44684480)
19. Melero-Martin JM, Khan ZA, Picard A, Wu X, Paruchuri S, Bischoff J (2007) In vivo vasculogenic potential of human bloodderived endothelial progenitor cells. Blood 109:4761-4768 (Pubitemid 46827769)
20. Khan ZA, Melero-Martin JM, Wu X, Paruchuri S, Boscolo E, Mulliken JB, Bischoff J (2006) Endothelial progenitor cells from infantile hemangioma and umbilical cord blood display unique cellular responses to endostatin. Blood 108:915-921 (Pubitemid 44154625)
21. Roelofs JJ, Rowshani AT, van den Berg JG, Claessen N, Aten J, ten Berge IJ, Weening JJ, Florquin S (2003) Expression of urokinase plasminogen activator and its receptor during acute renal allograft rejection. Kidney Int 64:1845-1853 (Pubitemid 37323716)
22. Zins K, Abraham D, Sioud M, Aharinejad S (2007) Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 67:1038-1045
23. Isik FF, Rand RP, Gruss JS, Benjamin D, Alpers CE (1996) Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res 61:71-76 (Pubitemid 26066031)
24. Hasan Q, Tan ST, Gush J, Peters SG, Davis PF (2000) Steroid therapy of a proliferating hemangioma: histochemical and molecular changes. Pediatrics 105:117-120
25. Huai Q, Mazar AP, Kuo A, Parry GC, Shaw DE, Callahan J, Li Y, Yuan C, Bian C, Chen L et al (2006) Structure of human urokinase plasminogen activator in complex with its receptor. Science 311:656-659 (Pubitemid 43191309)
26. Blasi F, Carmeliet P (2002) uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3:932-943 (Pubitemid 35477371)
27. Mazar AP (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res 14:5649-5655
28. Wong ET, Tergaonkar V (2009) Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 116:451-465
29. Schwabe RF, Sakurai H (2005) IKKbeta phosphorylates p65 at S468 in transactivaton domain 2. FASEB J 19:1758-1760 (Pubitemid 41429554)
30. Mattioli I, Geng H, Sebald A, Hodel M, Bucher C, Kracht M, Schmitz ML (2006) Inducible phosphorylation of NF-kappa B p65 at serine 468 by T cell costimulation is mediated by IKK epsilon. J Biol Chem 281:6175-6183 (Pubitemid 43847547)
31. Bredel M, Bredel C, Juric D, Duran GE, Yu RX, Harsh GR, Vogel H, Recht LD, Scheck AC, Sikic BI (2006) Tumor necrosis factor-alpha-induced protein 3 as a putative regulator of nuclear factor-kappaB-mediated resistance to O6-alkylating agents in human glioblastomas. J Clin Oncol 24:274-287 (Pubitemid 46622056)
32. Wei Y, Sowers JR, Clark SE, Li W, Ferrario CM, Stump CS (2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Endocrinol Metab 294:E345-351 (Pubitemid 351231460)
33. May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S (2000) Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. Science 289:1550-1554
34. Strickland I, Ghosh, S (2006) Use of cell permeable NBD peptides for suppression of inflammation. Ann Rheum Dis 65(Suppl 3):iii75-82 (Pubitemid 44629109)
35. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78:773-785 (Pubitemid 24294453)
36. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T (1995) The proteasome pathway is required for cytokine- induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506
37. Yang Y, Kitagaki J, Wang H, Hou DX, Perantoni AO (2009) Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci 100:24-28
38. Tobe M, Isobe Y, Tomizawa H, Nagasaki T, Takahashi H, Hayashi H (2003) A novel structural class of potent inhibitors of NF-kappa B activation: structure-activity relationships and biological effects of 6-aminoquinazoline derivatives. Bioorg Med Chem 11:3869-3878 (Pubitemid 36970113)
39. Takahashi K, Mulliken JB, Kozakewich HP, Rogers RA, Folkman J, Ezekowitz RA (1994) Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 93:2357-2364 (Pubitemid 24177146)
40. Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M (2002) Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci USA 99:7455-7460 (Pubitemid 34568712)
41. Scatena M, Almeida M, Chaisson ML, Fausto N, Nicosia RF, Giachelli CM (1998) NF-kappaB mediates alphavbeta3 integrininduced endothelial cell survival. J Cell Biol 141:1083-1093 (Pubitemid 28243974)
42. Klein S, de Fougerolles AR, Blaikie P, Khan L, Pepe A, Green CD, Koteliansky V, Giancotti FG (2002) Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol 22:5912-5922 (Pubitemid 34815839)
43. Franco AV, Zhang XD, Van Berkel E, Sanders JE, Zhang XY, Thomas WD, Nguyen T, Hersey P (2001) The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol 166:5337-5345 (Pubitemid 32374152)
44. Calicchio ML, Collins T, Kozakewich HP (2009) Identification of signaling systems in proliferating and involuting phase infantile hemangiomas by genome-wide transcriptional profiling. Am J Pathol 174:1638-1649
45. Orrington-Myers J, Gao X, Kouklis P, Broman M, Rahman A, Vogel SM, Malik AB (2006) Regulation of lung neutrophil recruitment by VE-cadherin. Am J Physiol Lung Cell Mol Physiol 291:L764-771 (Pubitemid 44498489)
46. Romashkova JA, Makarov SS (1999) NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401:86-90
47. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR (1999) Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 107:120-127 (Pubitemid 29133531)
48. Tao Y, Williams-Skipp C, Scheinman RI (2001) Mapping of glucocorticoid receptor DNA binding domain surfaces contributing to transrepression of NF-kappa B and induction of apoptosis. J Biol Chem 276:2329-2332
49. Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, Van der Saag PT (1995) Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids. Mol Endocrinol 9:401-412
50. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M (1995) Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 270:286-290
51. Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Gloss B, Lin SC, Heyman RA, Rose DW, Glass CK et al (1996) A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell 85:403-414 (Pubitemid 26160711)
52. Lee SK, Kim HJ, Na SY, Kim TS, Choi HS, Im SY, Lee JW (1998) Steroid receptor coactivator-1 coactivates activating protein- 1-mediated transactivations through interaction with the c-Jun and c-Fos subunits. J Biol Chem 273:16651-16654 (Pubitemid 28311685)
53. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ (2001) Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197 (Pubitemid 32762193)
54. Shibata A, Nagaya T, Imai T, Funahashi H, Nakao A, Seo H (2002) Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res Treat 73:237-243 (Pubitemid 34712997)
55. Kiriakidis S, Andreakos E, Monaco C, Foxwell B, Feldmann M, Paleolog E (2003) VEGF expression in human macrophages is NF-kappaB-dependent: studies using adenoviruses expressing the endogenous NF-kappaB inhibitor IkappaBalpha and a kinasedefective form of the IkappaB kinase 2. J Cell Sci 116:665-674 (Pubitemid 36231305)
56. Basseres DS, Baldwin AS (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 25:6817-6830 (Pubitemid 44657854)
57. Schmidt D, Textor B, Pein OT, Licht AH, Andrecht S, Sator- Schmitt M, Fusenig NE, Angel P, Schorpp-Kistner M (2007) Critical role for NF-kappaB-induced JunB in VEGF regulation and tumor angiogenesis. EMBO J 26:710-719
58. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26 (Pubitemid 38088695)